Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesOverexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells
BMC Cancer, 09/14/09
Li FQ et al. – HSp17 is aberrantly expressed in a significant proportion of epithelial ovarian carcinomas. Our results strongly suggest that HSp17 plays a role in metastatic disease and resistance of epithelial ovarian carcinoma to chemotherapy.
Methods- Immunohistochemistry and immunocytochemistry were used to identify HSp17 in paraffin embedded ovarian malignant tumor specimens and peritoneal metastatic malignant cells
- Then we examined the effect of HSp17 overexpression on the proliferation, migration, and chemoresistance of ovarian cancer cells to carboplatin and cisplatin in a human ovarian carcinoma cell line, HO8910
- HSp17 was aberrantly expressed in 43% (30/70) of the patients with primary epithelial ovarian carcinomas, and in all of the metastatic cancer cells of ascites from 8 patients
- The Sp17 expression was also detected in the metastatic lesions the same as in ovarian lesions
- None of the 7 non-epithelial tumors primarily developed in the ovaries was immunopositive for HSp17
- Overexpression of HSp17 increased the migration but decreased the chemosensitivity of ovarian carcinoma cells to carboplatin and cisplatin
Related Articles
Anti-apoptotic proteins Bcl-2/Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells
Infection and Immunity, 10/12/09
Relevance Score: 93%
Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level
Cancer Letters, 11/12/09
Relevance Score: 90%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 90%
Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer
Molecular Cancer, 10/13/09
Relevance Score: 89%
Cytotoxicity of natural extract from Tegillarca granosa on ovarian cancer cells is mediated by multiple molecules
Clinical and Investigative Medicine, 10/06/09
Relevance Score: 89%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Dysregulation of Platelet-Derived Growth Factor beta-Receptor Expression by deltaNp73 in Neuroblastoma
Molecular Cancer Research, 12/04/09
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression
Virchows Archiv, 12/04/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/04/09
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Vaginal Schwannoma in a case with uterine myoma
Annals of Diagnostic Pathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor